SCHEMBL4339753

SCHEMBL4339753

Nc1cccc2c(=O)c(C(=O)O)c[nH]c12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 3/20 0.63
CSNK2B P67870 3/20 0.63
CSNK2A1 P68400 3/20 0.63
KDM4E B2RXH2 3/20 0.62
ALDH1A1 P00352 3/20 0.62
HPGD P15428 3/20 0.62
DNA2 P51530 1/20 0.61
CASP6 P55212 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61
CYP1A2 P05177 2/20 0.55
HSD17B10 Q99714 1/20 0.55
TET2 Q6N021 1/20 0.51
TET1 Q8NFU7 1/20 0.51
CLEC4M Q9H2X3 1/20 0.47
PBRM1 Q86U86 1/20 0.45
POLB P06746 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.44
ALOX12 P18054 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18589537 0.85 CSNK2A2 (0.69) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL1244916 0.82 CSNK2A2 (0.65) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL2977498 0.81 KDM4E (0.67) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL2979929 0.81 CSNK2A2 (0.69) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL2976084 0.81 CSNK2A2 (0.63) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL11198811 0.80 CSNK2A2 (0.71) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL31157465 0.79 CSNK2A2 (0.61) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL28606562 0.79 KDM4E (0.65) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL11199520 0.79 CSNK2A2 (0.61) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1
SCHEMBL2977296 0.78 TSHR (0.64) CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
CN-101343251-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-11-09 CN disclosed
CN-101343250-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-09-21 CN disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
CN-101343251-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101343250-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101342169-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-100423721-C Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2008-10-08 CN disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed
US-4404201-A N-/ /ALKANOYLAMINOALKANOYLAMINO OR AMINOALKANOYL AMINO/-DIHYDRO-OXO-3-QUINOLINYLCARBONYL/- DERIVATIVES WARNER-LAMBERT COMPANY (US) 1983-09-13 US disclosed
US-4382089-A Antibacterial amide compounds, compositions thereof and methods of using them WARNER-LAMBERT COMPANY (US) 1983-05-03 US disclosed
US-4374138-A PENICILLINS WARNER-LAMBERT COMPANY (US) 1983-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CSNK2A2 4773/4885CSNK2B 4291/4885CSNK2A1 4673/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CSNK2A2 4773/4885CSNK2B 4291/4885CSNK2A1 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.